NKGen Biotech, Inc.

NKGen Biotech, Inc., trading under the ticker GFOR on Nasdaq, is the combined entity resulting from the de-SPAC merger between Graf Acquisition Corp. IV and clinical-stage biopharmaceutical company NKGen Biotech, a developer of natural killer cell therapies for oncology indications. Graf Acquisition Corp. IV, sponsored by Graf Acquisition LLC, completed its IPO in 2022, targeting the healthcare and biotechnology sector. The company filed a 10-K annual report on March 31, 2023, covering fiscal year 2022, as the transaction moved toward closing. The filing reflects the company's status as a pre-revenue clinical-stage biotech operating within the SPAC structure. For complete filing history, sponsor details, and deal analytics on GFOR and hundreds of other SPACs, sign up for full data access at SpacDesk.